KRAS and non-small cell lung carcinoma: In 124 patients with advanced-stage KRAS G12C-mutant NSCLC who had formerly received chemotherapy and/or immunotherapy, sotorasib demonstrated a 37.1% objective response rate (ORR), an 11.1-month median duration of response (DOR), a 6.8-month median PFS, and a 12.5-month median overall survival (OS) in the Phase I/II CodeBreaK 100 clinical study (Punekar et al., 2022).